指南与共识肿瘤 PET/CT核素与放射性配体治疗

EAU/ASCO关于阴茎癌前哨淋巴结活检的新指南推荐及核医学视角下的剩余挑战

New EAU/ASCO guideline recommendations on sentinel node biopsy for penile cancer and remaining challenges from a nuclear medicine perspective.
指南 / 共识 · Eur J Nucl Med Mol Imaging · 2024-01-13

欧洲泌尿外科学会(EAU)与美国临床肿瘤学会(ASCO)新近更新阴茎癌指南,强调动态前哨淋巴结活检(DSNB)为浸润性阴茎肿瘤且无可触及腹股沟淋巴结病变患者手术分期的首选方法。本文阐述该推荐依据,并描述DSNB在假阴性率、淋巴显像与SPECT/CT判读、示踪剂用量与注射部位优化等方面的剩余挑战及推广策略。

要点

  • EAU/ASCO新指南强调DSNB是浸润性阴茎肿瘤且无可触及腹股沟淋巴结病变患者手术分期的首选方法。
  • DSNB诊断准确性高且术后并发症最低,优于开放或微创腹股沟淋巴结清扫术。
  • DSNB的假阴性率及其对患者结局的潜在负面影响是推广中的主要挑战。

核心结论

  • DSNB历经多年显著发展,与核医学的专门努力和创新以及后续验证其疗效的临床研究相关。
  • DSNB现被强烈推荐用于选定的阴茎癌患者的手术分期。
  • 为进一步优化DSNB,需要多学科协作研究以改善前哨淋巴结识别,从而提高诊断准确性并减少并发症。

研究设计与样本

  • 本文为指南解读类文章,阐述EAU/ASCO新指南推荐依据并描述剩余挑战与推广策略。

主要发现

  • DSNB与开放或微创腹股沟淋巴结清扫术(ILND)相比,诊断准确性高且术后并发症最低,促使新指南将其列为首选。
  • DSNB的假阴性率及其对患者结局的潜在负面影响是阻碍其广泛采用的主要挑战。
  • 改进方向包括优化淋巴显像与单光子发射计算机断层成像/计算机断层成像(SPECT/CT)图像的采集时机与判读。
  • 需优化放射性药物的示踪剂用量与注射部位选择。
  • 手术中限制切除无示踪剂活性的淋巴结可能有助于降低并发症发生率。

关键数值与推荐

  • EAU/ASCO新指南强调DSNB是浸润性阴茎肿瘤且无可触及腹股沟淋巴结病变患者手术分期的首选方法。
  • DSNB被强烈推荐用于选定的阴茎癌患者的手术分期。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • DSNB存在假阴性率,并可能对患者结局产生潜在负面影响。
  • DSNB的广泛采用面临挑战,需在淋巴显像与SPECT/CT判读、示踪剂用量与注射部位、术中淋巴结切除范围等方面改进。
  • 为进一步优化DSNB,需要多学科协作研究以改善前哨淋巴结识别。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The European Association of Urology (EAU) and the American Society of Clinical Oncology (ASCO) recently issued updated guidelines on penile cancer, emphasising dynamic sentinel node biopsy (DSNB) as the preferred method for surgical staging among patients with invasive penile tumours and no palpable inguinal lymphadenopathy. This paper outlines the rationale behind this new recommendation and describes remaining challenges, as well as strategies for promoting DSNB worldwide. MAIN TEXT: DSNB offers high diagnostic accuracy with the lowest postoperative complications compared to open or minimally invasive inguinal lymph node dissection (ILND), prompting its preference in the new guidelines. Nevertheless, despite its advantages, there are challenges hampering the widespread adoption of DSNB. This includes the false-negative rate associated with DSNB and the potential negative impact on patient outcome. To address this issue, improvements should be made in several areas, including refining the timing and interpretation of the lymphoscintigraphy and the single photon emission computed tomography/computed tomography images. In addition, the quantity of tracer employed and choice of the injection site for the radiopharmaceutical should be optimised. Finally, limiting the removal of nodes without tracer activity during surgery may help minimise complication rates. CONCLUSION: Over the years, DSNB has evolved significantly, related to the dedicated efforts and innovations in nuclear medicine and subsequent clinical studies validating its efficacy. It is now strongly recommended for surgical staging among selected penile cancer patients. To optimise DSNB further, multidisciplinary collaborative research is required to improve SN identification for better diagnostic accuracy and fewer complications.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Vreeburg MTA, Donswijk ML, Albersen M, et al. New EAU/ASCO guideline recommendations on sentinel node biopsy for penile cancer and remaining challenges from a nuclear medicine perspective. Eur J Nucl Med Mol Imaging. 2024. PMID: 38216778. doi:10.1007/s00259-023-06586-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。